Home › Funds › Frazier Life Sciences Management, L.P. › PHAT

Frazier Life Sciences Management, L.P. position in PHAT

Phathom Pharmaceuticals, Inc. · Health Care

Frazier Life Sciences Management, L.P. reported holding 12,466,489 shares of PHAT (Phathom Pharmaceuticals, Inc.) in its Q2 2026 13F filing — a position valued at US$135.3M, representing 2.95% of its reported portfolio and ranking #9 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed PHAT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)12.47M sh
Reported value held$135.26M
Portfolio Weight2.95%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Frazier Life Sciences Management, L.P.'s PHAT position evolved

Frazier Life Sciences Management, L.P. first disclosed a stake in PHAT in Q3 2023 at 10,109,279 shares (US$104.8M). The position peaked in Q4 2025 at 12,466,489 shares, worth US$206.8M. Across 12 filings, Frazier Life Sciences Management, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 10 time(s). The most recent filing (Q2 2026) shows 12,466,489 shares valued at US$135.3M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 10.11M $104.83M New
Q4 2023 10.11M $92.30M Hold
Q1 2024 10.11M $107.36M Hold
Q2 2024 10.11M $104.13M Hold
Q3 2024 10.11M $182.78M Hold
Q4 2024 10.11M $82.09M Hold
Q1 2025 10.11M $63.39M Hold
Q2 2025 12.47M $119.55M Add
Q3 2025 12.47M $146.73M Hold
Q4 2025 12.47M $206.82M Hold
Q1 2026 12.47M $138.50M Hold
Q2 2026 12.47M $135.26M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PHAT and 13F data

PHAT (Phathom Pharmaceuticals, Inc.) is a Health Care company. 30 other funds we track also report a position in PHAT — the largest reported positions include Medicxi Ventures Management (Jersey) Ltd (US$81.0M), Carlyle Group Inc. (US$37.9M), NEA Management Company, LLC (US$21.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PHAT

All PHAT fund holders →

FAQ

How long has Frazier Life Sciences Management, L.P. held PHAT?

Frazier Life Sciences Management, L.P. has disclosed PHAT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Frazier Life Sciences Management, L.P.'s current position in PHAT?

As of Q2 2026, Frazier Life Sciences Management, L.P. holds 12.47M shares of PHAT (Phathom Pharmaceuticals, Inc.), valued at $135.26M, representing 2.95% of its reported portfolio and ranking #9.

Has Frazier Life Sciences Management, L.P. been buying or selling PHAT?

In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. held unchanged its position in PHAT. The position peaked in Q4 2025 at 12.47M shares.

Which other funds hold PHAT?

Other major institutional holders of PHAT include Medicxi Ventures Management (Jersey) Ltd, Carlyle Group Inc., NEA Management Company, LLC, among 30 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.